Q1 EPS Forecast for BioLife Solutions Increased by Analyst

BioLife Solutions, Inc. (NASDAQ:BLFS) – Investment analysts at Northland Capmk increased their Q1 2025 earnings per share (EPS) estimates for BioLife Solutions in a report released on Monday, March 3rd. Northland Capmk analyst C. Byrnes now anticipates that the medical equipment provider will earn ($0.02) per share for the quarter, up from their previous forecast of ($0.03). The consensus estimate for BioLife Solutions’ current full-year earnings is ($0.30) per share. Northland Capmk also issued estimates for BioLife Solutions’ Q2 2025 earnings at ($0.01) EPS and FY2025 earnings at ($0.03) EPS.

BioLife Solutions (NASDAQ:BLFS) last issued its quarterly earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 EPS for the quarter, beating the consensus estimate of ($0.06) by $0.32. The firm had revenue of $22.71 million during the quarter, compared to analysts’ expectations of $21.73 million. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. During the same period in the prior year, the firm posted ($0.21) earnings per share.

A number of other brokerages have also weighed in on BLFS. Benchmark reiterated a “buy” rating and set a $30.00 target price on shares of BioLife Solutions in a research note on Thursday, December 19th. HC Wainwright lowered their price objective on BioLife Solutions from $29.00 to $27.00 and set a “buy” rating on the stock in a research note on Monday, November 18th. TD Cowen raised their price objective on BioLife Solutions from $28.00 to $31.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Northland Securities raised their price objective on BioLife Solutions from $28.00 to $31.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 8th. Finally, Craig Hallum raised their price objective on BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. One research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, BioLife Solutions has an average rating of “Moderate Buy” and a consensus price target of $29.43.

BioLife Solutions Price Performance

NASDAQ:BLFS opened at $26.25 on Thursday. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03. The stock’s 50 day moving average price is $26.67 and its two-hundred day moving average price is $25.48. The firm has a market capitalization of $1.22 billion, a price-to-earnings ratio of -24.76 and a beta of 1.91. BioLife Solutions has a 12-month low of $14.84 and a 12-month high of $29.55.

Institutional Investors Weigh In On BioLife Solutions

Several hedge funds have recently modified their holdings of BLFS. Steward Partners Investment Advisory LLC acquired a new position in shares of BioLife Solutions in the fourth quarter worth approximately $26,000. Mark Sheptoff Financial Planning LLC acquired a new position in shares of BioLife Solutions in the 3rd quarter worth approximately $28,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of BioLife Solutions in the 4th quarter valued at $31,000. Quest Partners LLC acquired a new stake in shares of BioLife Solutions during the third quarter worth $57,000. Finally, 1620 Investment Advisors Inc. increased its position in shares of BioLife Solutions by 41.7% during the fourth quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider’s stock worth $60,000 after buying an additional 675 shares during the period. Institutional investors and hedge funds own 93.24% of the company’s stock.

Insider Activity at BioLife Solutions

In related news, EVP Aby J. Mathew sold 7,604 shares of the firm’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $27.33, for a total transaction of $207,817.32. Following the sale, the executive vice president now owns 276,315 shares of the company’s stock, valued at $7,551,688.95. This trade represents a 2.68 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Troy Wichterman sold 987 shares of the firm’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $27.02, for a total value of $26,668.74. Following the sale, the chief financial officer now directly owns 121,779 shares in the company, valued at approximately $3,290,468.58. This trade represents a 0.80 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 11,978 shares of company stock valued at $322,724 in the last 90 days. 2.20% of the stock is owned by corporate insiders.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.